Abbott has reported new data from its prospective, non-randomised Volt CE Mark Study, indicating that individuals treated ...

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

SGLT2 inhibitors, compared with GLP1 agonists, significantly lower risk for atrial fibrillation in patients with type 2 diabetes.

Atrial fibrillation remains a common and challenging cardiac arrhythmia, particularly in hypertensive patients, who face a ...

HealthDay News — For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed anticoagulants in the year after discharge, although some ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...

Medtronic (MDT) announced positive clinical outcomes from two studies in atrial fibrillation, AFib, patients treated with the Affera family of ...

Pulsed field ablation (PFA) technology made some advances with 12-month results for the Globe Pulsed Field System in ...

Three risk factors—high blood pressure, atrial fibrillation, and smoking—are more likely to cause severe strokes, meaning ...

Average and brisk walking paces were associated with significantly lower risks for all cardiac arrhythmias, atrial fibrillation, and other arrhythmias compared with slow walking paces. HealthDay News ...